NCT01680991 2016-04-25A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant DiseaseHoffmann-La RochePhase 1 Completed48 enrolled 27 charts
NCT01292135 2014-07-24Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL)Pharmacyclics LLC.Phase 1 Completed33 enrolled 13 charts